Abstract: A Saishin N derivative represented by the following general formula: ##STR1## wherein X represents a carbonyl group or a >CH--ORx group, or X bonds to a carbon atom in Y or Z to represent a >C(ORx)--O-- group; Y and Z may be the same or different and each represents a carbonyl group or a >CH--ORy group, or each bonds to an oxygen atom in X to represent a >CH-- group; the broken line represents an optional bond; and Rx and Ry may be the same or different and each represents a hydrogen atom or an alkyl, alkenyl, aralkenyl, aralkyl, heterocyclic-alkyl or acyl group, is provided which is therapeutically usable as an antiulcer agent.

Abstract: 3-Tetrazolylpyrido[1,2-a]pyrimidin-4-one derivatives useful as an antiallergy agent are produced by reacting a cyano derivative of pyrido[1,2-a]pyrimidin-4-one compound with (i) hydrazoic acid, followed by hydrolysis, or with (ii) a salt of hydrazoic acid, reacting the resulting product with an acid or a base, followed by hydrolysis.

Abstract: An optically active (+)-isomer of a benzoquinolizine compound of the formula [I], is provided: ##STR1## where X.sub.1 represents a halogen atom, and R.sub.1 and R.sub.2 represent lower alkyl groups, a physiologically acceptable salt thereof, or a hydrate of either of the foregoing compounds. The compounds [I]-(+) exhibit an excellent antibacterial activity. Also, the compounds exhibit high solubility in water. Therefore, the compounds of the present invention are usable for the treatment of infectious diseases and usable in aqueous liquid preparations such as injections.

Abstract: Pyrido[1,2-a]pyrimidine derivatives of the general formula [I] and their physiologically acceptable salts are provided: ##STR1## where R is a hydrogen atom, a halogen atom or a methyl group, and n is a whole number of 0, 1 or 2. The pyrido[1,2-a]-pyrimidine derivatives and their salts exhibit an excellent antagonistic effect on slow-reacting substance of anaphylaxis and, therefore, are useable for the treatment of allergic diseases.

Abstract: A surface active material may be produced from the lung tissue of mammal by means of employing an acetone-treatment procedure as well as an organic solvents mixture-treatment procedure other than the conventional procedures of differential centrifugation, density gradient centrifugation and dialysis. The chemical composition of the active material has for example, a phospholipid content of 75.0-95.5%, a neutral lipid content of 1.8-14.0%, total cholesterol content of 0.0-3.0%, carbohydrate content is 0.1-1.5% and protein content is 0.5-5.0%, all based on the dried weight of the material. The pharmaceutical composition containing the surface active material defined as above is usable for clinical treatment of human hyaline-membrane disease.